Background {#Sec1}
==========

Osteoarthritis (OA) is a major cause of pain, functional limitation and disability worldwide \[[@CR1]\], with hip and knee OA ranked as the 11th highest contributor to global disability and 38th highest in disability-adjusted life years (DALYs) \[[@CR2]\]. Treatment remains focussed on managing pain, which is ranked by patients as the highest treatment priority \[[@CR3]\]. However, pain control remains poor in 50% of non-operatively treated patients \[[@CR4]\]. Despite the large disease burden, currently no approved disease modifying OA drugs (DMOADs) are available.

OA is a heterogeneous, complex disease with multiple phenotypes \[[@CR5], [@CR6]\]. Few treatments have been demonstrated to be effective for OA pain and to slow down changes in structure, and this may be partly due to treating everyone as if they have the same pathological process. Treatment can be optimised by selecting study populations by subgroups with specific features that are likely to respond to targeted treatments. One such phenotype is an inflammatory phenotype.

OA is typically considered a 'non-inflammatory' type of arthritis; however, localised low-grade inflammation is an important factor in OA pathogenesis, with inflammatory patterns observed both early \[[@CR7]\] and late \[[@CR8]\] in the disease process. In OA, inflammatory changes have been demonstrated both systemically and in the affected joint. Moreover, there is now evidence that inflammation helps distinguish clinically distinct phenotypes of OA \[[@CR9]\].

Elevated levels of systemic inflammation (as observed by high sensitive C reactive protein (hsCRP) \[[@CR10]\] are observed in persons with OA compared to controls, and are positively correlated with the degree of synovial inflammatory infiltration in OA \[[@CR11]\]. hsCRP levels are associated with both symptoms and disease markers, with higher hsCRP levels associated with greater pain (in both a meta-analysis \[[@CR10]\] and longitudinal data from our centre \[[@CR12]\]), decreased physical function \[[@CR10]\], decreased cartilage volume \[[@CR13]\] and disease progression \[[@CR7], [@CR14]\]. Therefore, systemic inflammation predicts both pain and structural outcomes in OA.

Inflammation also occurs locally within joints. Pro-inflammatory cytokines, including interleukin (IL)-1β, tumour necrosis factor-α (TNF-α), and IL-6 are produced by synovium and chondrocytes, and contribute to the progression of cartilage degradation \[[@CR8]\]. Localised inflammation presents as effusion (excess synovial fluid within the joint space) and/or synovitis (thickening of the synovium); these predict pain \[[@CR15]--[@CR18]\], including new and worsening pain over 2.6 years \[[@CR18]\]. Effusion-synovitis also predicts structural changes--- cartilage defects, bone marrow lesions (BMLs) and increased cartilage loss over 2.6 years \[[@CR19]\]---and joint replacement \[[@CR20]\]. Thus, stopping the cascade of inflammation is likely to slow down deleterious changes in knee structure and reversing inflammation has the potential to improve outcomes globally in knee OA.

High levels of inflammation in OA can be targeted with treatments including oral prednisolone \[[@CR21]\] or biologics \[[@CR22]\], but these therapies are expensive and have too many side effects for widespread use. Safer treatments for reducing inflammation are needed.

Fish oil is effective in people with rheumatoid arthritis (RA), reducing pain \[[@CR23]\], morning stiffness and number of painful and/or tender joints \[[@CR23], [@CR24]\], and non-steroidal anti-inflammatory drug (NSAID) consumption \[[@CR23], [@CR25]\]. This is an effective add-on therapy to standard RA therapies, reducing the risk of treatment failure and increasing the rate of remission \[[@CR26]\]. Efficacy data on the use of marine-sourced oils is more limited in people with OA. Observational data suggest that omega-6 and omega3 polyunsaturated fatty acids from dietary sources may have beneficial effects on synovitis and cartilage damage cross-sectionally \[[@CR27]\], but that use of a variety of marine oils is ineffective for OA pain \[[@CR28], [@CR29]\], although there is marked heterogeneity amongst the predominantly poor quality trials \[[@CR28]\], and none were enriched for participants with evidence of an inflammatory phenotype. Canola oil/low dose fish oil may be effective \[[@CR29]\]. However, unlike marine oils in general, oil from Antarctic krill (*Ephausia superba*, a zooplankton crustacean) may be effective in people with OA. Like fish oil, it is high in eicosapentanoic acids (EPA) and decosahexanoic acid (DHA) \[[@CR30]\], although the chemical structures of the fatty acids differ (phospholipids, rather than triacylglycerol or fatty acid ethyl esters); but unlike fish oil, it also naturally contains antioxidants (predominantly astaxanthin \[[@CR30]\]). Additionally, bioavailability of krill oil is better than fish oil, as comparable amounts of EPA and DHA are obtained from lower doses of krill oil compared to fish oil \[[@CR31]\]. In animal studies, krill oil supplementation had larger effects on most clinical outcomes than fish oil \[[@CR32]\], while krill oil reduced the severity of inflammatory arthritis in mice by 50% compared to controls \[[@CR32]\]. In mice transgenic for human TNF-α, both fish and krill oil improved plasma cholesterol levels, but only krill oil had additional beneficial effects on markers of fatty acid oxidation \[[@CR33]\]. Therefore, bioavailability data and animal studies suggest that krill oil has anti-inflammatory and anti-oxidative effects and may be a better treatment in vivo than fish oil.

Two randomised controlled trials (RCTs) including people with osteoarthritis have demonstrated that daily krill oil (300 mg \[[@CR34]\] or 2 g \[[@CR35]\]) is effective in reducing some aspect of knee pain \[[@CR34], [@CR35]\], functional impairment \[[@CR34], [@CR35]\], and stiffness \[[@CR35]\]. However, these RCTs have methodological limitations, including being of short duration (30 days), having poor documentation of adverse events, not including any imaging data to determine the effect of krill oil on knee structures, and not targeting patients with evidence of inflammation.

Therefore, we aim to compare, using a randomised, placebo-controlled double-blind design over 6 months, the effect of 2 g krill oil daily compared to identical placebo, on knee pain and MRI-detected knee effusion-synovitis size (primary outcomes) in participants with clinical knee OA, significant knee pain and effusion-synovitis on MR imaging over 24 weeks.

Objective {#Sec2}
=========

We are conducting a multi-centre randomised, placebo-controlled double-blind clinical trial. This will compare efficacy of krill oil vs identical placebo to treat knee OA (both pain and structure) in 260 patients with clinical knee OA, significant knee pain and effusion-synovitis on imaging.

We hypothesise that krill oil (2 g daily) will decrease pain (assessed by 100 mm visual analog scale (VAS)) score by 10 mm more than identical placebo over 24 weeks and decrease effusion-synovitis size over 24 weeks (co-primary hypotheses) and improve knee pain over 4, 8, 12, 16, and 20 weeks (secondary hypotheses) in patients with symptomatic knee OA and knee effusion-synovitis, compared with placebo. If krill oil proves effective, it will offer a novel therapeutic approach to reduce knee OA progression.

Methods/design {#Sec3}
==============

Study design {#Sec4}
------------

This randomised trial of krill oil for OA of the knee (KARAOKE) study is a multicentre, randomised, double-blind, placebo-controlled superiority trial over 24 weeks. The trial was registered on the Australian New Zealand Clinical Trials Registry prior to recruitment, and trial reporting will be guided by the Consolidated Standards of Reporting Trials (CONSORT) statement \[[@CR36]\]. We aim to recruit a convenience sample of 260 patients with clinical knee OA, significant knee pain and effusion-synovitis visualised on MRI. Patients will be recruited via the OA Clinical Trial Network, at Australian public hospitals in Melbourne, Sydney, Adelaide and Perth and a research institute in Hobart, using a combined strategy, including collaboration with general practitioners, rheumatologists and orthopaedic surgeons, as well as advertising through local and social media. Patients will be encouraged to contact their local research nurse via email or telephone.

Inclusion criteria {#Sec5}
------------------

Inclusion criteria are as follows: males and females aged ≥ 40 years; with significant knee pain on most days (defined as a pain score ≥ 40 mm on a 100-mm VAS); and meeting the American College of Rheumatology (ACR) criteria for symptomatic knee OA \[[@CR37]\], assessed by a physician, and any effusion-synovitis present on MRI (defined as grade 1 or more according to modified WORMS scoring \[[@CR18], [@CR38]\]).

Exclusion criteria {#Sec6}
------------------

Exclusion criteria are as follows: Significant knee injury within the last 6 monthsUse of anticoagulants, high dose aspirin or NSAIDs, as krill oil is contraindicated in such peopleUnwillingness to stop taking krill oil and fish oil medications 30 days prior to the trial and during the trial (minimum washout 4 weeks)Other forms of inflammatory arthritis (especially rheumatoid arthritis and gout)Seafood allergyArthroscopy or open surgery in the "study" knee in the last 12 monthsInjections of corticosteroids (last 3 months) or hyaluronic acid (last 6 months) in the index kneeWomen who are pregnant or breastfeedingUse of any investigational drug(s) and/or devices within 30 days prior to randomisationPresence of any serious medical illness that may preclude 24-week follow-upInability to provide informed consentInability to have an MRI (claustrophobia, pacemakers, metal in eyes, metal in knees that disrupt the images at the area of interest)Severe knee OA (joint space narrowing (JSN)) on x-ray of grade 3 using the Osteoarthritis Research Society International (OARSI) atlas \[[@CR39]\])

Randomisation and blinding {#Sec7}
--------------------------

Study participants were allocated to receive either krill oil or placebo in a 1:1 ratio based on computer-generated random numbers using a central randomisation website hosted by the University of Tasmania using adaptive allocation (minimisation) \[[@CR40]\]. Briefly, the randomisation program examined the number of participants that were currently assigned to each of the two arms and then adjusted the randomisation thresholds so that the arm with the fewest participants would have a greater chance of being selected. Randomisation will be stratified by study site and is accessible by a dedicated website. This will be conducted by staff members with no direct involvement in the study.

The randomised controlled trial will be a double-blind one, with both patients and investigators assessing outcomes blinded to treatment allocation. Allocation concealment and double blinding will be ensured by: 1) use of identical softgels for each group; 2) objective measures of knee structural changes being made by trained observers blinded to group allocation; and 3) subjective measures being taken by research nurses blinded to group allocation.

Emergency unblinding will be allowed in limited situations that impact on the safety of study patients. Code-break for the full randomisation schedule will be maintained by the University of Tasmania. Patients who are unblinded will be withdrawn from treatment but will continue to be followed as per the planned follow-up schedule.

Intervention {#Sec8}
------------

Eligible people will receive 2 × 1 g softgels daily of either krill oil or placebo for 6 months. The krill oil (Superba Boost product) contains 190 mg/g of EPA and 100 mg/g of DHA. The total omega-3 content is 350 mg/g, total omega-6 is 12 mg/g, hence the omega-3 to omega-6 ratio is 29. The placebo used is a mixture of vegetable oils (virgin cold pressed olive oil, maize oil, palm kernel oil, medium chain triglycerides), containing no EPA or DHA, and less than 5 mg/g (0.5%) other omega-3s (predominantly oleic acid (C18:1n9) and linoleic acid (C18:2n6)). Both the krill oil and the placebo are provided in non-distinguishable opaque glycerin softgels. A small amount of vanilla flavour added to the shell of both active and placebo softgels to ensure uniform taste and smell. All patients will continue usual care by their treating health practitioners.

Study procedure and time points {#Sec9}
-------------------------------

Research assistants will first conduct screening over the telephone. If early checks of study eligibility are favourable, participants will be booked in for a face-to-face screening visit to further determine eligibility and explain what is involved in the study. At the screening face-to-face visit, patients will complete questionnaires, have a knee x-ray and MRI, supply a blood sample and have a clinical assessment by a study doctor to ensure inclusion criteria are met. The study knee will be defined as the one with symptomatic OA meeting all inclusion criteria. If both knees meet these criteria, the study doctor will decide which is the study knee, typically the one with the highest pain score.

Table [1](#Tab1){ref-type="table"} outlines the schedule of assessments. After screening, there will be three study visits (weeks 0, 12 and 24). The same research assistants, who are blinded to treatment allocation, will measure all clinical variables, administer questionnaires, monitor compliance and record adverse events at these visits. Additional questionnaire mail outs will occur monthly. MRI scans will occur at screening and week 24; knee x-ray will be performed at screening; blood samples are taken at screening, 12 and 24 weeks, and urine samples are taken at baseline and week 24. Table 1Schedule of assessments, KARAOKE studyVisit/week numberScreeningBaseline (week 0)4812162024Informed consentxKnee x-rayxKnee MRIx\*xClinical measures Bloodsxxx Clinical examinationx Leg strengthxxx Height and weightxx Capsules givenxx Capsule countxx Pressure pain testing (Melbourne/Perth only)xxx Ultrasound (Perth)xxQuestionnaire measures Knee VASxxxxxxxx Knee WOMACxxxxxxx Knee ICOAPxxxxxxx Patient global evaluationxxxxxxx Joint replacement surgeryxxx Concomitant medicationsxxx Safety (AEs)xx Hand VAS, back VASxxxxxxx AQoLxxx Patient health questionnaire (PHQ-9)x Pain at other sitesxxx Treatment guessingxx painDETECTx Adverse eventsAs required Early withdrawalAs required\*if otherwise suitable

Participants will discontinue involvement in the study if they need to use drugs that are contraindicated (marine oils, anticoagulants, high dose aspirin, NSAIDs), they stop taking study medication or the participant or the site investigators request discontinuation.

Quality assurance {#Sec10}
-----------------

To ensure high-quality execution of the trial in accordance with the protocol, all trial staff will be trained by the chief investigators and provided with a standard protocol book which contains details of standard operating procedures, trial contacts, visits, measurements, monitoring and case report forms. Data are collected using the same forms across sites, these data are checked by staff in Hobart and any discrepancies are clarified.

Primary outcomes {#Sec11}
----------------

We have two primary outcomes for this study, assessing improvements in symptoms and structural progression. These are change in knee pain assessed by VAS over 24 weeks and change in effusion-synovitis volume assessed from MRI. All outcomes and time points of assessment are listed in Table [2](#Tab2){ref-type="table"}. Table 2Primary and secondary outcomesOutcomeTime pointsPrimary outcomes Knee pain: VAS score24 weeks Knee effusion-synovitis: maximal area, volume, ordinal measures (MRI)24 weeksSecondary outcomes BML: maximal area24 weeks Effusion volume (ultrasound)^γ^24 weeks Knee pain: VAS score4, 8, 12, 16, 20 weeks Knee pain: total WOMAC pain, weight bearing and non-weight bearing painall time points Hand and back pain (VAS)All time points Knee functionAll time points OMERACT--OARSI responder criteria \[[@CR41]\]All time points hs-CRP12 and 24 weeks Blood lipids12 and 24 weeks Blood glucose12 and 24 weeks Leg strength12 and 24 weeks Analgesic useAll time points Quality of life (AQoL-6D)12 and 24 weeks Pressure pain threshold testing on study knee^¥^24 weeks Adverse events12 and 24 weeks Medication persistence12 and 24 weeksCost data: hospitalisation, medication use, joint replacement^γ^ Perth only^¥^ Melbourne and Perth ONLY

Other outcome measures {#Sec12}
----------------------

### Pain intensity {#Sec13}

Knee pain, back pain and hand pain will be assessed using a 100 mm VAS by asking "on this line, thinking about your study knee/back/most painful hand, where would you rate your pain, using the last 7 days as a time frame" over 4, 8, 12, 16 and 20 (but not 24) weeks.

We will also assess pain using the Western Ontario and McMasters Universities Osteoarthritis Index (WOMAC) \[[@CR42]\], also over the preceding 7 days. Five items of the WOMAC pain scale in 100-mm VAS format \[[@CR43]\] will be used to assess pain during walking on a flat surface, going up and down stairs, at night while in bed, sitting or lying, and standing upright during the last 7 days. Items will be summed to create a total WOMAC pain score (range 0--500). Incomplete items will be addressed according to the WOMAC user guide \[[@CR44]\]. If only one item is missing, the remaining four items will be averaged and then multiplied by five. The WOMAC pain score will be considered invalid if more than one item is missing.

### Knee function {#Sec14}

Knee function will be assessed using WOMAC \[[@CR42]\]. Seventeen items of the WOMAC function scale in 100-mm VAS format \[[@CR43]\] will be used to assess function during descending stairs, ascending stairs, rising from sitting, standing, bending to floor/picking up an object, walking on flat surface, getting in/out of the car, going shopping, putting on socks/stockings, rising from bed, taking off socks/stockings, lying in bed, getting in/out of the bath, sitting, getting on/off the toilet, heavy domestic duties, and light domestic duties during the last 7 days. Items will be summed to create a total WOMAC function score (range 0--1700). If two or fewer items are missing, the remaining items will be averaged and then multiplied by 17 \[[@CR44]\]. The WOMAC function score will be considered invalid if more than two items are missing.

### Magnetic resonance imaging outcomes {#Sec15}

An MRI scan of the "study" knee will be performed (screening, week 24). Knees will be imaged in the sagittal plane on a 1.5 T or 3 T whole-body magnetic resonance unit using a dedicated knee coil. Sequences will include T2-weighted fat saturation three-dimensional (3-D) fast spin echo sequence (effusion-synovitis volume, cartilage defects, BMLs); T1-weighted fat saturation 3-D gradient-recalled acquisition sequence (cartilage volume, cartilage thickness); and T2 mapping (Table [3](#Tab3){ref-type="table"}). Table 3Magnetic resonance imaging sequences and parametersStudy siteMachine and coilsT2 weighted sagittal 3DT1-weighted sagittal 3DT2 mappingHobart1.5 T whole-body MR unit (GE Optima 450 W, Milwaukee, USA), using a dedicated Transmit/Receive 8-channel knee coil where patient size permits, if body habitus is too large we use a 16 channel large GEM Flex coilT2 weighted fat-saturated 3D fast spin echo sequence; repetition time 2300 ms; echo time 80 ms; field of view 18 cm; 256 × 256 matrix with interpolation Recon Voxel 0.35 × 0.35 × 1 mm; 2 excitation; slice thickness 1 mmT1-weighted fat-saturated 3D gradient-recalled acquisition; flip angle 30 degrees; repetition time 38 ms; echo time 3 ms; field of view 16 cm; 256 × 160 matrix Reconstructed Voxel 0.625 × 1 × 1.5 mm; 1 excitation; slice thickness 1.5 mmT2 mapping; repetition time 1100 ms; echo time 6.6 ms; field of view 16 cm; 320 × 224 matrix Reconstructed Voxel 0.5 × 0.714 × 3 mm; 1 excitation; slice thickness 3 mmPerth1.5 T whole-body MR unit (Siemens, Magnetom Avanto Fit, Erlangen, Germany), using a dedicated Transmit/Receive 15 channel knee coilT2 weighted fat-saturated 3D fast spin echo sequence; flip angle mode T2; repetition time 1400 ms; echo time 89 ms; field of view 19 cm; 256 × 256 matrix with interpolation Recon Voxel 0.4 × 0.4 × 1.5 mm; 1 excitation; slice thickness 1.5 mmT1-weighted fat-saturated 3D gradient-recalled acquisition; flip angle 10 degrees; repetition time 13.9 ms; echo time 6.05 ms; field of view 19 cm; 320 × 298 matrix Reconstructed Voxel 0.6 × 0.6 × 1.5 mm; 1 excitation; slice thickness 1.5 mmT2 mapping (multi echo SE); flip angle 180 degrees; repetition time 1890 ms; echo time 13.8, 27.6, 41.4, 55.2, 69.0 ms; field of view 16 cm; 256 × 256 matrix Reconstructed Voxel 0.63 × 0.63 × 3 mm; 1 excitation; slice thickness 3 mmAdelaide3 T whole-body MR unit (Siemens Magnetom Skyra 3Tesla), using a dedicated 15 channel knee coilT2 weighted fat-saturated 3D SPACE; repetition time 2200 msec; echo time 121 msec; field of view 16 cm; 320 × 320 matrix; 1 excitation; slice thickness 0.6 mmT1-weighted Water Excitation 3D gradient-recalled acquisition VIBE; flip angle 16 degrees; repetition time 10.4 ms; echo time 5.7 ms; field of view 160 cm; 320 × 298 matrix; 1 excitation; slice thickness 1 mmT2 mapping (multi echo acquisition); flip angle 180 degrees; repetition time 1750 ms; echo time 13.8/27.6/41.4/55.2/69 ms; field of view 16 cm; 320 × 320 matrix; 1 excitation; slice thickness 3 mmMelbourne3 T whole-body MR unit (Siemens, (Skyra 3 T) Magnetom Avanto Fit, Erlangen, Germany), using a dedicated Transmit/Receive 15 channel knee coilT2 weighted fat-saturated 3D fast spin echo sequence; flip angle mode T2; repetition time 1200 ms; echo time 50 ms; field of view 16 cm; 230 × 320 matrix without interpolation not on; Recon Voxel 0.5 × 0.5 × 0.6 mm; 1 excitation; slice thickness 0.6 mmT1-weighted fat-saturated 3D gradient-recalled acquisition; flip angle 30 degrees; repetition time 11.7 ms; echo time 5.61 ms; field of view 16 cm; 320 × 320 matrix Reconstructed Voxel 0.5 × 0.5 × 1.5 mm; 1 excitation; slice thickness 1.5 mmT2 mapping (multi echo SE); flip angle 180 degrees; repetition time 1840 ms; echo time 11.7, 23.4, 35.1, 46.8, 58.5 ms; field of view 16 cm; 307 × 384 matrix Reconstructed Voxel 0.4 × 0.4 × 3 mm; 1 excitation; slice thickness 3 mmSydney3 T whole-body MR unit (Siemens, Magnetom Skyra, Erlangen, Germany), using a dedicated Transmit/Receive 15 channel knee coilT2 weighted fat-saturated 3D fast spin echo sequence; flip angle mode T2; repetition time 1000 ms; echo time 108 ms; field of view 16 cm; 256 × 256 matrix without interpolation Recon Voxel 0.6 × 0.6 × 0.6 mm; 1 excitation; slice thickness 0.6 mmT1-weighted fat-saturated 3D gradient-recalled acquisition; flip angle 25 degrees; repetition time 11.6 ms; echo time 4.7 ms; field of view 16 cm; 256 × 256 matrix Reconstructed Voxel 0.6 × 0.6 × 1 mm; 1 excitation; slice thickness 1 mmT2 mapping (multi echo SE); flip angle 180 degrees; repetition time 2150 ms; echo time 13.8, 27.6, 41.4, 55.2, 69.0 ms; field of view 16 cm; 384 × 326 matrix Reconstructed Voxel 0.42 × 0.42 × 3 mm; 1 excitation; slice thickness 3 mm

#### Knee effusion-synovitis {#FPar1}

Effusion-synovitis is defined as the presence of intra-articular fluid-equivalent signal on T2 weighted MRI sequence (Fig. [1](#Fig1){ref-type="fig"}). A modified Whole-Organ Magnetic Resonance Imaging Score (WORMS) scoring system will be utilised to assess effusion-synovitis (grade 0 to 3) semi-quantitatively in four regions of interest (ROI; suprapatellar pouch, central portion, posterior femoral recess, subpopliteal recess) in terms of the estimated maximal distention of the synovial cavity. The greatest score for any of the four ROI will be used as maximal effusion of the knee. The intraclass reliability assessed as weighted κ in 50 randomly selected images was 0.63--0.75 in different subregions, and the interclass inter-rater reliability was 0.65--0.79 \[[@CR45]\]. Fig. 1Example of changes in effusion-synovitis area (cm^2^). Effusion-synovitis size decreased from baseline to follow-up 2.6 years later (**a**, **b**). Effusion/synovitis are present in both the suprapatellar pouch and central portion. Overall, effusion size is smaller at follow-up MRI

Effusion-synovitis volume will be measured using a semi-automated segmentation method according to the intra-articular fluid-equivalent signal on a section-by-section basis in each ROI. The final 3-D volume rendering will be generated using commercial in-house imaging software. Change in effusion-synovitis volume is calculated by subtracting baseline values from follow-up values. The intra-rater reliability was 0.97 in the whole joint (0.98 in suprapatellar pouch and 0.95 in central portion). The inter-rater reliability was 0.99 in the whole joint (0.99 in suprapatellar pouch and 0.93 in central portion). Effusion-synovitis volume was highly correlated with effusion-synovitis score (rho 1/4 0.77, *P* \< 0.01 for total; rho 1/4 0.91, *P* \< 0.01 for suprapatellar pouch; and rho 1/4 0.77, *P* \< 0.01 for central portion) \[[@CR46]\].

Differentiating effusions from synovitis on MR images requires administration of a contrast agent (gadolinium), which may cause nephrotoxicity. While this is rare, we do not consider the benefits of such differentiation between synovitis and effusion justifies the risk to our study participants, and hence we have not used it.

#### Bone marrow lesions {#FPar2}

Bone marrow lesions (BMLs) will be defined as an ill-defined hyperintensity area in the subchondral bone on MRI. BMLs will be assessed on the sagittal T2 weighted sequences at the medial tibial, medial femoral, lateral tibial, lateral femoral and patella sites using a modified WORMS scoring system \[[@CR47]\]. The maximum size of each lesion will also be measured using software cursors applied to the greatest area of the lesion, as previously described \[[@CR48]\]. We have demonstrated an intraclass correlation coefficient (ICC) of 0.97 \[[@CR49]\] using this method. Total BML size will be calculated as the sum of every lesion within the medial tibial, medial femoral, lateral tibial, lateral femoral and patella sites.

### Ultrasound {#Sec16}

Knees will be imaged using an Esaote Mylab 70 VXG ultrasound machine in Perth (Table [4](#Tab4){ref-type="table"}), with scans undertaken by a single sonographer. Images will be stored to be re-read to determine intra-reader reliability). Table 4Ultrasound parametersSuprapatellar pouchMedial para patellaLateral para patellaKnee position30 degrees flexionNeutralNeutralProbe planeLongitudinalTransverseTransverseProbe positionProbe on the distal thigh, at midline, longitudinal to its major axisOne end of the probe over the patella and the other endover the medial femoral condyleOne end of the probe over the patella and the other endover the lateral femoral condyleModesGS and PDGS and PDGS and PDSettingsTo be optimised once machines knownTo be optimised once machines knownTo be optimised once machines knownProbe sweepMove lateral to medial sideProximal to distal sideMove proximal to distal sideLesions to scoreSynovitis (0--3)Synovial hypertrophy (0--1)Effusion (0--1)Effusion depth (mm)Synovial power Doppler signal (0--1)Synovitis (0--3)Synovial hypertrophy (0--1)Effusion (0--1)Effusion depth (mm)Synovial power Doppler signal (0--1)Synovitis (0--3)Synovial hypertrophy (0--1)Effusion (0--1)Effusion depth (mm)Synovial power Doppler signal (0--1)Images to storeMidline longitudinal with the effusion depth measurement in situRepresentative imageRepresentative image*GS* grey scale, *PD* power DopplerUltrasounds completed in Perth only

Synovitis in the supra patella pouch will be defined as a combination of synovial hypertrophy and effusion (using Outcome Measures in Rheumatology (OMERACT) definitions \[[@CR50]\]) and scored on a 0--3 scale with grade 0 = no synovitis, grade 1 = minimal distension of the recess by abnormal internal hypoechoic or anechoic (relative to subdermal fat tissue) material, grade 2 = moderate distension or enlargement of the recess by abnormal internal hypoechoic or anechoic (relative to subdermal fat tissue) material with flat or concave superficial limit, and grade 3 = severe distension or enlargement of the recess by abnormal internal hypoechoic or anechoic (relative to subdermal fat tissue) material with bulging superficial limit. Depth of effusion (mm) will be measured only in the suprapatellar pouch (SPP), from a still midline longitudinal image, measuring the maximal effusion depth in this plane.

In the SPP, medial parapatellar region and lateral parapatellar region, synovial hypertrophy, effusion and power doppler signal (defined using OMERACT definitions \[[@CR50]\]) will be scored as absent (0) or present (1).

### Pressure pain threshold testing {#Sec17}

Pressure pain threshold (PPT) testing will be conducted using a pressure algometer (FDN200, Wagner Instruments, USA) with a probe area of 1 cm^2^, which exerts pressures of up to 200 N/cm^2^/2000 kPa. The PPT is determined using an ascending stimulus intensity (slowly increasing ramps of 50 kPa/s (\~ 0.5 kg/cm^2^s) applied bilaterally over the three test sites: the affected joint (knee, assessed over the tibial below the medial joint line), an unaffected joint (ipsilateral proximal radioulnar joint), and over the thenar eminence. The study participant is asked to notify the examiner as soon as the sensation becomes painful, and the pressure exerted recorded. The PPT is determined by the mean of the threshold from a series of three stimulus intensities each applied as a slowly increasing ramp of 50 kPa/s \[[@CR51]\].

### OMERACT--OARSI responder criteria {#Sec18}

Response to krill oil will be assessed using the OMERACT--Osteoarthritis Society International (OARSI) set of response criteria \[[@CR41]\]. Participants will be classed as responding if they have high improvement in pain (using the VAS) or function (using WOMAC function scale) of ≥ 50% and absolute change ≥ 20; or if they have positive relative (≥ 20%) or absolute (≥ 10) change in two out of three of pain, function or patient's global assessment.

### Lower limb muscle strength {#Sec19}

Lower limb muscle strength is a key correlate of pain and typically increases when pain reduces \[[@CR52]\]. We will assess lower limb leg strength in both legs simultaneously, using a dynamometer (TTM Muscular Meter, Tokyo, Japan) as previously described \[[@CR21]\]. This is done in duplicate and the mean of the two estimates is used. The muscles measured in this technique are mainly the quadriceps and hip flexors. The previously published repeatability estimate (Cronbach's α) for this method is 0.91 \[[@CR53]\].

### Measure of intermittent and constant osteoarthritis pain {#Sec20}

Intermittent and constant osteoarthritis pain (ICOAP) is a multidimensional OA-specific measure designed to comprehensively evaluate the pain experience in people with hip or knee OA. This includes pain intensity, frequency, and impact on mood, sleep and quality of life, independent of the effect of pain on physical function \[[@CR54]\], over the past 7 days. It contains 11 items in two domains with two supplementary items on intermittent pain predictability, and uses rating scales with five categories of response, e.g., "not at all," "mildly," "moderately," "severely," and "extremely" \[[@CR54]\]. Each ICOAP item is scored from 0 to 4; missing data are dealt with according to rules in the user guide \[[@CR55]\]. Scores are produced for each subscale separately by summing subscale scores for each item and then normalising each score from 0 (no pain) to 100 (extreme pain). The ICOAP is reliable (Cronbach's α 0.93, ICC 0.85 \[[@CR54]\]) and valid \[[@CR54]\].

### Quality of life {#Sec21}

Quality of life will be assessed using the Assessment of Quality of Life (AQoL-6D) questionnaire, which assesses six separately scored dimensions (Independent Living, Relationships, Mental Health, Coping, Pain and Senses), each with variable item numbers and response levels \[[@CR56]\]. The AQoL-6D has good psychometric properties \[[@CR57]\]. Utility scores will be calculated based on methods published on the AQoL website \[[@CR56]\] with a range 0--1 where 0 indicates the worst health state and 1 the best.

### Blood samples {#Sec22}

Fasting blood samples will be obtained from study participants at screening, 12 and 24 weeks. Samples will be analysed for fasting glucose, lipids (total, HDL and LDL) and hsCRP. The blood will be either tested fresh or stored at − 80 °C.

Other assessments {#Sec23}
-----------------

### Radiographs {#Sec24}

A standing anteroposterior semiflexed radiograph of the 'study' knee will be performed at screening. X-rays will be scored for joint space narrowing and osteophytes on a four point scale (0--3) using the OARSI atlas \[[@CR39]\]. In our hands this method has very high reproducibility with an ICC of 0.98 for joint space narrowing and 0.99 for osteophytes \[[@CR58]\].

### Anthropometry {#Sec25}

These include height (stadiometer) and weight (electronic scales) and body mass index (BMI) (weight/height^2^) measured at weeks 0, 12 and 24.

### painDETECT {#Sec26}

Neuropathic pain will be assessed by the painDETECT questionnaire (− 1 to 38) at screening to provide information on level of nociceptive and/or neuropathic contributions to pain. A painDETECT score \< 12 is defined as unlikely neuropathic pain, and 13--18 as possible neuropathic pain \[[@CR59]\].

### Concomitant medication {#Sec27}

Use of pain medicines will be recorded by questionnaire at all visits. Participants will be asked to keep medications as stable as possible (including NSAIDs) and use paracetamol as rescue medication. Use of fish and krill oil during the trial will not be permitted, and use must cease 2 weeks prior to randomisation. Participants who commence anti-coagulant therapy will be withdrawn from the trial. We will assess analgesic use from the medication data.

### Treatment guessing and adherence {#Sec28}

Study participants will be asked what treatment they think they received at the 12- and 24-week assessments with the following options: krill oil, placebo, or not sure.

Adherence to treatment will also be assessed at the 12- and 24-week assessments by standard pill count methods \[[@CR60]\].

### Safety assessment {#Sec29}

Adverse events will be monitored throughout the study. Standard safety and efficacy monitoring will be performed through regular face-to-face visits and phone calls between visits. The patients are requested to report any adverse events to the research staff spontaneously. Details of the adverse event and its relationship with study intervention will be recorded and reported to the local Human Research Ethics Committees in accordance with the requirements of individual committees.

Sample size calculations {#Sec30}
------------------------

Using data from another trial conducted in our centre \[[@CR52]\], assuming 10-mm difference between krill oil and placebo on the VAS pain scale (reduction in VAS pain scores in the placebo group by − 15.5 ± 25.5 mm over 12 weeks) and using assumptions of 90% power and 5% probability of type 1 error (alpha = 0.05), we will need 234 participants. Adjusting for 10% loss to follow-up, we need 260 participants (130 in each arm). Based on data on effusion-synovitis volume in our vitamin D RCT for knee OA, there was 13.7 ml (SD = 10.7) in the placebo group and 13.6 ml (8.1) in the active group (in those with effusion-synovitis at enrolment, i.e., 60%) at baseline \[[@CR61]\]. With 234 subjects we will have 90% power to detect a difference of 4.5 ml. It is likely we will see at least a reduction of this amount with a treatment that effectively targets inflammation. What level reflects clinical significance is uncertain but this level is approximately 2.5 times the change that could be expected with measurement error. Furthermore, modelled data from our long-term Tasmanian cohort demonstrates that a reduction in effusion-synovitis size by 4.5 ml will decrease the need for joint replacement by 30% over 13 years (unpublished data).

Statistical analysis {#Sec31}
--------------------

The primary analyses will be intention-to-treat analyses of primary and secondary outcomes. Per protocol analyses will be performed as the secondary analyses.

Changes in knee pain, knee effusion-synovitis size and any other outcomes which were collected using a linear scale will be analysed using a linear mixed model with treatment, month and their interaction (treatment × month) as covariates, as well as outcome measured at baseline and the baseline interaction with month. Incidence of adverse events will be assessed using log binomial regression. Correlated data within trial centres and the repeated measures will be addressed using trial centre and patient identification as random intercepts. Month will be treated as random effect to allow different treatment effects among patients over time. The sensitivity of models to the structure for the random effects and covariance structures will be assessed using likelihood ratio tests. Change in outcome measures within each group and differences in changes between groups from baseline to follow-up will be calculated using linear combinations of the estimated coefficients. If there are baseline imbalances in covariates between treatment groups, we will consider adjusting for them based on whether we regard the imbalance as clinically significant. Missing data caused by loss to follow-up and non-responses will be addressed by adding variables that have complete data at baseline and can explain missingness to the regression models.

Secondary analysis for missing data will be performed in people with full medication adherence (e.g., \> 80% of softgels) and using imputation. Baseline variables with complete data will be used for data imputation assuming missing at random.

Subgroup analyses will be performed to examine which subgroups may respond better to treatment. These will include effusion size, radiographic knee OA, co-pathology present on MRI, pain characteristics, levels of inflammatory markers and serum lipid measures. Statistical significance will be set as a two-sided *P* value \< 0.05.

Data integrity and management {#Sec32}
-----------------------------

Data will be recorded using case report forms and processed centrally at the Menzies Institute for Medical Research, University of Tasmania. The hard copies of case report forms will be stored in a locked area at each study site with secured and restricted access. The electronic data will be stored on password-protected servers with restricted access. All data collected will be kept strictly confidential. Daily backups of all electronic data will occur to minimise any risk of lost data. Data transfer will be encrypted with all data de-identified. Only members of the research team who need to contact study patients, enter data or perform data quality control will have access to patient information.

After study completion, paper copies of data will be archived in secure storage. Identifiers will not be removed in case follow-up of study patients is necessary; however, electronic data will continue to be kept in a secure electronic database. This will remain password protected and with access given only to the study investigators unless otherwise authorised by the study team.

Withdrawal {#Sec33}
----------

If patients withdraw from the study before 6 months of follow-up, the reason and date will be recorded. An early MRI will be considered for participants who can not make the final visit.

Roles and responsibilities and monitoring {#Sec34}
-----------------------------------------

The University of Tasmania (as the trial sponsor) and the principal investigators are responsible for all aspects of the trial, including design, conduct and oversight. The principal investigators will monitor the conduct and progress of the project at each site. The trial coordinator will visit each study site to make sure that all trial procedures are compliant with the trial protocol. The principal investigators and the research team will have regular teleconferences to ensure efficient study execution and ongoing monitoring of the study progress, with summary documents circulated after each meeting. Krill oil has a good safety profile \[[@CR31]\] and is available over-the-counter, so we do not plan to use a data safety monitoring board. The trial is also being monitored at each site by a practicing rheumatologist.

Dissemination plans {#Sec35}
-------------------

The results of this study will be presented at conferences and published in scientific journals. Any notes or publications arising from our research will be de-identified. Only aggregate statistical results will be presented.

The outcomes of the project will be disseminated to study patients using non-technical language. Dissemination of the overall study findings to the patients will occur in a de-identified manner and be based on the entire study population. The scientific paper will be available for dissemination to study participants.

Discussion {#Sec36}
==========

We propose a multicentre, randomised, double blind placebo-controlled trial to determine whether krill oil 2 g/day improves knee pain and reduces size of knee effusion-synovitis compared to placebo in people with clinical knee OA, significant knee pain and knee effusion-synovitis. If krill oil proves effective, it will offer a novel therapeutic approach to reduce or slow progression of knee OA.

Krill oil is theorised to have an effect via both anti-inflammatory and anti-oxidative mechanisms. Oxidative stress and inflammation have important roles in OA pathogenesis and krill oil therapy may be beneficial in treating OA. Krill oil (300 mg/day) reduced inflammation (as measured by CRP) by 30% in 30 days vs 25% increase in patients receiving placebo \[[@CR34]\]. This may have important clinical implications, with low level inflammation associated with increased loss of tibial cartilage volume (β = − 1.18% per annum per quartile of IL-6) \[[@CR62]\]). Accordingly, trials are starting to use MRI-assessed effusion/synovitis as a treatment target. In a trial using low dose oral prednisolone for painful hand OA, MRI-assessed effusion-synovitis was associated with pain cross-sectionally, but not hand pain as assessed by VAS; however, effusions did not change over time with treatment or predict response to treatment \[[@CR63]\].

Effusion and synovitis can also be assessed using ultrasound; such effusions predict knee replacements independent of severity of radiographic damage and pain \[[@CR20]\]. Presence of ultrasound-detected knee effusions has been used to select people who might respond well to oral methotrexate, which demonstrated efficacy in an open-label trial, albeit without a control group \[[@CR64]\]. However, the reproducibility of ultrasound is largely dependent on the operator and ultrasound is not yet well utilised in clinical trials of knee OA. This study will enable comparisons of MRI vs ultrasound indices in assessing change in effusion volume and provide evidence of which imaging modality is of most use in this context.

In summary, knee OA is a major but poorly understood public health problem with no pharmacologic therapies that affect disease progression. Two small trials \[[@CR34], [@CR35]\] suggest that krill oil will improve knee pain and may reduce systemic inflammation in people with OA. If krill oil can reduce knee pain and effusion size in knee OA, study findings will be readily translated into clinical practice as krill oil is already popular and available over the counter despite limited evidence of efficacy.

Trial status {#Sec37}
------------

Trial status: Completed recruiting.

Protocol version number and date: Scientific protocol V2 (08 April 2016), Standard operating procedures: V4 (Hobart site, 13 November 2017), V3 (Adelaide site, 23 August 2016).

Date recruitment began: 06 December 2016, recruitment complete July 2019.
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**Additional file 1.** SPIRIT 2013 checklist: Recommended items to address in a clinical trial protocol and related documents.

3-D

:   Three-dimensional

ACR

:   American College of Rheumatology

AE

:   Adverse event

AQoL

:   The Assessment of Quality of Life

BMI

:   Body mass index

BMLs

:   Bone marrow lesions

CONSORT

:   Consolidated Standards of Reporting Trials

DALYs

:   Disability-adjusted life years

DHA

:   Decosahexanoic acid

DMOADs

:   Disease-modifying OA drugs

EPA

:   Eicosapentanoic acids

GS

:   Grey scale

HDL

:   High density lipoproteins

hsCRP

:   High sensitive C reactive protein

ICC

:   Intraclass correlation coefficient

ICOAP

:   Measure of intermittent and constant osteoarthritis pain

IL

:   Interleukin

JSN

:   Joint space narrowing

KARAOKE

:   Randomised trial of krill oil for osteoarthritis of the knee

LDL

:   Low density lipoproteins

MRI

:   Magnetic resonance imaging

NHMRC

:   National Health and Medical Research Council

NSAIDs

:   Non-steroidal anti-inflammatory drug

OA

:   Osteoarthritis

OARSI

:   Osteoarthritis Research Society International

OMERACT

:   Outcome Measures in Rheumatology

PD

:   Power Doppler

PPT

:   Pressure pain testing

QoL

:   Quality of life

RA

:   Rheumatoid arthritis

RCTs

:   Randomised controlled trial

ROI

:   Regions of interest

SD

:   Standard deviation

TASOAC

:   Tasmanian Older Adult Cohort

TNF-α

:   Tumour necrosis factor-α

UTAS

:   University of Tasmania

UTN

:   Universal Trial Number

VAS

:   Visual analogue scale

WOMAC

:   Western Ontario and McMasters Universities Osteoarthritis Index
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